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patients (15.2%) of 2984 treated, and third line 529 patients (33%) of 1603 treated.We
found similar results using the IMPACT database: 2,256 (7.8%) CRC patients had a
test ordered for K-ras between 2005 and 2010. K-ras testing increased with line of
therapy: first line 244 patients (7.8%), second line 510 (14.6%), and third line 650
patients (33.1%). EMR lab results from stage IV disease (n349) consisted of 15%
mutated type, 60% unknown and 25% wild type. For confirmed test results wild
type represented 62.5% and mutated type 37.5%. CONCLUSIONS: Over the last six
years, use of K-ras testing has increased in use in patients with CRC. The increase
has occurred in later lines of therapy. The timing occurring late in therapy may
limit the use of agents specific for this test.
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OBJECTIVES: The aim of this study is to evaluate the accuracy of non-invasive
diagnosis methods for ischemic heart disease in patients with chest pain.
METHODS:A retrospective cohort study was performed on new patients who have
not received any diagnosis of ischemic heart disease or treatment before among
those over 30 years of agewho visited the cardiology outpatient clinic between 2006
to 2008 in a single medical institution. Among non-invasive diagnostic methods,
stress ECG(sECG), myocardial SPECT, and CT coronary angiography(CTCA) were
included in our study. Since coronary angiography(CAG) was not performed in all
patients, the comparison of test accuracy was calculated by correcting referral bias
to CAGdepending onnon-invasive test results based on the Bayes Theorem, and by
reflecting the 1-year follow-up results. RESULTS: Among 4743 patients selected,
2485 patients received more than one of the following non-invasive tests: sECG,
SPECT, and CTCA for differential diagnosis. sECG was performed in 853 pa-
tients(34.3%), SPECT in 997 patients(40.1%), andCTCA in 635 patients(25.6%). A total
of 592 patients(23.8%) received CAG among the 2485 patients. Test indices adjusted
for referral bias using the 2 methods were a sensitivity of 49% or 80% in sECG, 46%
or 75% in SPECT and 57% or 88% in CTCA, a specificity of 65% or 62%, 81% or 78% in
SPECT and 96%or 81% inCTCA. A likelihood ratio for a positive testwere 1.39 or 2.08
in sECG, 2.47 or 3.38 in SPECT and 14.14 or 4.65 in CTCA, and a likelihood ratio for a
negative test were 0.79 or 0.33 in sECG, 0.66 or 0.32 in SPECT and 0.45 or 0.14 in
CTCA. CONCLUSIONS: In conclusion, the accuracy of diagnosing ischemic heart
disease was the highest in CTCA, followed by myocardial SPECT and sECG by cor-
recting referral bias to CAG.
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OBJECTIVES: To evaluate long-term clinical outcomes of elderly Medicare benefi-
ciaries who underwent non-emergent coronary stenting.METHODS: This popula-
tion-based prospective study analyzed patients in a large nationally representative
administrative claims database. The sample consisted of Medicare patients aged
65 who underwent a non-emergent coronary stent between 2006 and 2010. Pa-
tients were identified by existence of a hospital claim for a bare metal stent (ICD-
9-CM procedure code 36.06) or drug-eluting stent (ICD-9-CM procedure code 36.07
or codes 36.06 and 36.07). Eligible patients were followed one to five years after
stenting to assess risk of revascularization, myocardial infarction (MI), coronary
artery bypass surgery (CABG), and death. Long-term clinical outcomes were based
on HEDIS 2010 technical specifications. RESULTS: The study population included
26,023 patients that underwent a coronary bare-metal stent (female  40.15%, age
 75.38 ( 6.66), history ofMI 7.97%, history of CABG 1.01%) and 74,448 patients
that underwent a coronary drug-eluting stent (female  40.17%, age  73.78 (
6.19), history of MI  7.39%, history of CABG  1.27%). Patients with drug-eluting
stents had a lower risk of revascularization (29.57% vs. 31.65%, p  0.001), CABG
(1.40% vs. 2.57%, p  0.001), and mortality (4.96% vs. 9.25%, p  0.001) within one
year follow-up after stenting. There was no significant difference in the risk for MI
within one to four years follow-up (3.35% vs. 3.29%, p  0.05), but there was a
significant difference in risk of MI at five year follow-up (7.33% vs. 3.36%, p 0.001).
Mortality rates significantly increased over time in patientswith a bare-metal stent
whilemortality rates for thosewith a drug-eluting stent remained relatively stable.
CONCLUSIONS: The use of drug-eluting stents was significantly correlated with a
decline in long-term risk of revascularization, CABG,MI anddeath in comparison to
bare-metal stents.
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OBJECTIVES: About 10-15% of individuals with diabetes mellitus develop foot ul-
cers which precede 85% of amputations. Increased oxygen exposure, through the
use of hyperbaric oxygen therapy (HBOT), has been suggested to encourage ulcer
healing thus reducing the risk of amputation. The objective of this systematic
review is to evaluate the efficacy of systemic HBOT for non-healing ulcers of the
lower limb in diabetes patients. METHODS: A systematic search of the published
literature was conducted using controlled and keyword terms focusing on “HBOT”
and “lower limb diabetic ulcers”. Databases searched included Medline, EMBASE,
CINAHL, PubMed, Wiley’s Cochrane Library, and Biosis. Randomized controlled
trials (RCTs) and observational studies were included and no year or language
limits were employed. Two reviewers screened the articles. Pooled estimates of
outcomes were calculated using Review Manager when appropriate. RESULTS: Of
the 543 citations identified, 152 articles underwent full-text review. Data was ab-
stracted from 27 publications (7 RCTs, 9 comparative observational, and 11 non-
comparative observational studies). Primary outcomes of rates of amputation (ma-
jor or minor) and wound healing were identified. Relative risk (RR) estimates from
RCTs in the pooled analysis reflect a significant reduction inmajor amputation (RR
 0.32, 95% CI 0.11 to 0.91) with HBOT. For the proportion of unhealed wounds,
HBOT is also favoured (RR  0.45, 95% CI 0.32 to 0.64). CONCLUSIONS: The limited
RCT evidence surrounding the efficacy of HBOT favours the use of HBOT for non-
healingwounds of the lower limb for diabetes patients. Rigorous clinical trials with
larger sample sizes, however, need to be conducted to more conclusively establish
the benefits and harms of treating diabetic lower limb ulcers with HBOT.
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OBJECTIVES: The increasing use of both PET scan and surgical lymph node evalu-
ation in the cervical cancer (CC) treatment has led to a clinical debate. The objective
of this study is to provide a cost analysis of routine PET imaging in the work-up of
CC. METHODS: A decision-tree model was designed to compare pre-treatment
evaluation including PET-scan versus FIGO staging. Primary outcome was correct
primary treatment (CPT) due to the use of PET or FIGO. Cost effectiveness ratios
were calculated and results were expressed in terms of incremental cost effective-
ness ratio (ICER). The model used the SEER 2011 database (n12,200), for number,
incidence, and stage distribution of CC. Medicare reimbursement rates were used
for costs. Lymph nodemetastasis rates for each stage, and performance character-
istics of PET were abstracted from published data. Cited values were used and
varied over for sensitivity analysis. RESULTS: The addition of PET-scan to FIGO
clinical staging for IA1 CC resulted in 6(0.5%) more CPTs than FIGO staging at
baseline. In stage IA2, 75(6%) more CPT were performed and 187(14%) in stage IB1,
and an additional 322(24%) in IB2. In stage IIA, PET-scan resulted in an additional
50(3%) CPT (ICER$75,575), compared to 234(12%) CPT (ICER$61,509) in stage IIB,
and 333(26%) additional CPT in stage IIIA, (ICER $48,293). In stage IIIB and IVA the
addition of PET resulted in 240(19%) more CPT, and 41(8%) additional CPT in stage
IVA (ICER$52,791 vs.$71,810). Outcomes were sensitive to changes in prevalence
and PET performance in the sensitivity analysis.CONCLUSIONS:Routine pre-treat-
ment PET-scan may be cost effective for stage IA2-IB2 CC. The inclusion of PET-
scan in the pre-treatment evaluation of stage I CC increased the number of CPT
with an elevated ICER. The findings of this model need to be validated in the
clinical-setting to generate knowledge on best resources’ allocation.
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OBJECTIVES: Low dose computed tomography (CT) is the current recommended
lung cancer screening modality for selected high risk population. The role of bio-
markers is not clear. The objective of our study is to investigate the role of biomark-
ers in lung cancer screening via a systematic review andmeta-analysis.METHODS:
A systematic review is performed by reviewing primary studies focusing on bio-
markers for lung cancer screening using the following keywords (lung cancer) AND
((screen*) OR (diagnosis) OR (diagnostic) OR (prediagnostic) OR (detection) OR (pre-
dict*) OR (development)) AND ((biomarker) OR (blood) OR (serum) OR (sera) OR
(plasma) OR (antibodies) OR (urin*) OR (sputum) OR (exhale*) OR (volatile) OR (epi-
thelium)OR (epithelial) OR (bronchial) OR (airway)) in the title/abstract in Pubmed®
on December 31, 2011. We further limited our search to clinical trials, meta-anal-
ysis, or randomized controlled trials published for the past 5 years in English. Two
independent reviewers identified studies compatible for selection criteria and data
extraction after consensuswas reached.Manual searching for relevant studieswas
also performed from relevant studies. A randomeffectmodel was used to calculate
the pooled diagnostic performance of biomarker screening. RESULTS: Among the
identified studies (n172), three studies were included. In total, 1932 participants
received various kinds of biomarkers screening. By using these biomarkers to dif-
ferentiate cancer from non-cancer, the estimated pooled sensitivity and specificity
with 95% confidence interval was 40% (24%  57%) and 96% (94%  97%)
respectively. CONCLUSIONS: The diagnostic performance of biomarkers for lung
cancer screening is fair based on very limited data as found in this systematic
review. The role of biomarkers in lung cancer screening deserves further studies.
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OBJECTIVES: The objective of the study was to evaluate the budget impact of shift-
ing the treatment formenorrhagia in Canadian hospitals from rollerball to thermal
balloon ablation. Thermal balloon ablation procedures can be completed in an
ambulatory care setting as compared to rollerball procedures, which must be car-
ried out in the operating room. The aim of this study was to determine whether
shifting procedures from rollerball to thermal balloon ablation would present a
hospital with cost savings on a per patient basis. METHODS: A budget impact
model was created and populated using case-costing data from several large Ca-
nadian hospitals. The two procedures were compared in terms of device cost, use
of resources and nursing costs. The cost of treatment using rollerball and thermal
balloon ablationwere compared to determine the number of procedures that could
be completed using each device for the same total cost. RESULTS: Based on model
calculations the total cost per patient to treat menorrhagia using rollerball is
$1,977.58 and the total cost per patient to treat menorrhagia using thermal balloon
ablation is $1,415.46. The use of thermal balloon ablation allows for a hospital
savings of $562.12 per patient treated. The use of thermal balloon ablation would
enable a Canadian hospital to treat approximately 70 patients with menorrhagia
for the same total cost as treating 50 patients with rollerball. CONCLUSIONS: The
use of thermal balloon ablation for the treatment of menorrhagia allows for a cost
savings per patient when compared with rollerball.
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OBJECTIVES: Use of vascular closure devices for sealing the femoral artery follow-
ing percuatneous coronary diagnostic and interventional procedures has become a
routine practice. The collagen-based closure device system Angio-Seal™ has been
shown to be effective in decreasing time to hemostasis after coronary procedures.
Budgetary impact of replacing manual compression with Angio-Seal™, however,
has not been explored. We sought to evaluate the budget impact of using Angio-
Seal™ from the hospital perspective as it relates to clinical and economic
outcomes. METHODS: A customizable Excel®-based budget impact model was
built from a hospital perspective for a hypothetical cohort of 400 patients (200
interventional and 200 diagnostic) over a period of one year. Cost components
included device cost, facility cost (recover room costs) and nursing cost. A decision
treemodel was utilized to convert the expected probabilities of vascular complica-
tions into expected costs. Probabilities and costs were derived from published
meta-analyses and observational studies. Costs were converted to 2011 US dollars.
Sensitivity analysis was carried out over reported ranges of values formajor inputs
of the model. RESULTS: Using Angio-Seal™ in 100% of the cases resulted in esti-
mated cost savings of $255,498 per year compared to manual compression. Angio-
Seal™ usage resulted in cost savings for both interventional and diagnostic cases.
Cost savings were most sensitive to the variation in time and costs spent in the
recovery room as well as to the probabilities of groin bleeding and retroperitoneal
hemorrhage. Results were robust to changes in input variables. CONCLUSIONS:
Analysis shows that Angio-Seal™ represents a potential cost saving option for
institutions to achieve hemostasis after percutaneous coronary procedures with-
out increasing the risk of vascular complications. Given the current evidence on
safety and effectiveness of same-day discharge percutaneous coronary proce-
dures, Angio-Seal™ adds a potential cost savings dimension that can facilitate
adoption of this clinical practice.
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OBJECTIVES: Contrast agents for computer tomography (CT) are presented in glass
or plastic vials or syringes. Those containers take a lot of volume and are of con-
siderable weight resulting in important costs for storage and waste processing.
There is also a risk for injuries with sharp lips and spilling due to breakage. Those
containers need the use of small medical devices to allow injection of contrast
agents. The ScanBag® container was developed to overcome these problems. The
objectives of this study were to assess the impact on the hospital budget of using
Scanbag® instead of other containers. METHODS: According to the Ispor recom-
mendations for budget impact models (BIMs), we developed a BIM to demonstrate
the economical advantage of using contrast agents in ScanBag® from a hospital
perspective. Resource use in terms of broken products, injuries, storage, waste
management, small medical devices, and mono- or multipatient use for each pre-
sentation type were collected via literature and expert interviews in public and
private radiology centers in France, Belgium, Germany, Italy, Spain and the United
Kingdom. RESULTS: Replacing 1000 glass vials of 200 ml iobitridol by the same
volume in ScanBag® reduces broken products and injuries by 100%, storage space
by 43.8% and waste weight by 89.4%. Total cost savings for this simulation range
from €7076 in Germany to €8484 in Italy when costs of broken products, injuries,
storage, wastemanagement and small medical devices are considered. Depending
on the injector used, cost savings of up to €6,700 can be obtained for small medical
devices. CONCLUSIONS: Only in changing glass vials to ScanBag®, costs for hospi-
tals can be reduced through savings in broken products, injuries, storage andwaste
management. Largest cost savings are made on small medical devices.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving rapid, irregular heartbeats (Fuster et
al. 2006). AF patients are likely to have co-morbidities such as congestive heart
failure (CHF) and stroke (Lee et al. 2008). The prevalence of AF in adults is 1% in
adults 55 years, but increases to as much as 10% by age 80 (Go et al. 2001). The
purpose of this study was to estimate the economic burden of AF in selected de-
veloping countries based on prevalence and direct health care costs. METHODS:
The economic burdens of AF in Brazil, China, India, Russia, and Turkey were cal-
culated based on prevalence rates identified via a literature search. Annual prob-
abilities for health care interventions and related costs (e.g.: management of AF,
stroke and CHF), and associated disability costs were included in the model. The
adult populationwas adjusted for the percentage of the populationwho had access
to health care. If cost data were unavailable, costs were imputed based on the ratio
of per capita health expenditures between the United States and country of inter-
est. Sensitivity analysis was performed for the health care accessible population.
RESULTS: The prevalence of AF in adults in the countries studied was: 226,000 in
Turkey; 430,000 in Brazil; 497,000 in Russia; 778,000 in India; and 1.8 million in
China. The estimated annual economic burden of AF was: 159 million in Turkey;
412 million in Brazil; 5.7 billion in Russia; 1.25 billion in India; and 2.5 billion in
China (2010 local currencies). Sensitivity analysis revealed that the results could be
substantially higher. CONCLUSIONS: The economic burden of AF in developing
countries is potentially substantial given the large populations in these countries.
Proper management of AF is becoming increasingly important in countries where
access to health care has constantly been improved.
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OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens
and is characterized by uncoordinated atrial activation involving a rapid and irreg-
ular heart rate (Fuster et al. 2006). AF patients are likely to have concomitant con-
gestive heart failure (CHF) and stroke (Lee et al. 2008). The prevalence of AF in
adults 65 years is 5 - 6%, increasing with age (Go et al. 2001). The purpose of this
study was to estimate the economic burden of AF in selected developed countries
based on prevalence and direct health care costs.METHODS:The economic burden
ofAF in theUnited States (US), Canada, Germany, France, UnitedKingdomand Italy
was modeled based on prevalence rates identified via a literature search. Annual
probabilities of receiving health care treatment and associated costs for AF, stroke
and CHF, and related disability costs were included in the model. If cost data were
unavailable, the costs were imputed based on the ratio of annual per capita health
expenditures between theUnited States and the country of interest. Cost estimates
were calculated in 2010 rates of the local currencies. RESULTS: The prevalence of
AF in adults aged 65 in the countries studied was: 172,000 in Canada; 328,000 in
theUnitedKingdom; 348,000 in France; 391,000 in Italy; 533,000 inGermany; and 1.6
million in the United States. The estimated annual economic burden of AFwas: 597
million in Canada; 596 million in the United Kingdom; 1.23 billion in France; 840
million in Italy; 1.58 billion in Germany; and 9.75 billion in the United States (2010
local currencies). CONCLUSIONS: The economic burden of AF in developed coun-
tries is substantial, and is expected to grow as the population ages. Early detection
and appropriate management of AF may help reduce this economic burden.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat (Fuster
et al. 2006). The prevalence of AF is1% in adults55 years old, but increases to as
much as 10% by age 80 (Go et al. 2001). The purpose of this studywas to forecast the
incidence of AF in selected countries for 2015, 2020 and 2025 based on predicted
prevalence. METHODS: The prevalence of AF in Brazil, Canada, China, India, the
United Kingdom and United States (US) was forecasted based on prevalence rates
identified via a literature search and 2010 estimates of AF prevalence. Population
forecasts for the selected countries were taken fromUnited Nations Department of
Economic and Social Affairs forecasts. The adult population was adjusted for the
percentage of the population with access to health care. The model assumed cur-
rent age-adjusted prevalence rates would remain constant through 2025. One-way
sensitivity analysis was performed for the health care accessible population and
the country forecasted population. RESULTS: The prevalence and economic bur-
den is forecasted to increase from 0% to 2% per year in the selected countries. In
2025, the prevalence and economic burden ranged from 282,000 and 245 million
Lira in Turkey to 2.68 million and $17 billion in the United States. The burden is
reported in 2010 local currencies. Sensitivity analyses revealed that prevalence in
developing countries were most affected by health care accessibility. In developed
countries, prevalence was most affected by forecasted population growth.
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